| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
Fate Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN |
| 28 Sep 2026 |
8-K: Other Events
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge |
| 15 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the plan is the Fate Therapeutics, Inc. Third Amended and Restated 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Cons... |
| 04 Jun 2026 |
8-K: Other Events
TRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies Accessible to AllTM CORPORATE PRESENTATION June 2026 | NASDAQ: FATE | Non-Confidential © 2026 Fate Therapeutics. All rights reserved |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026 |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No C... |
| 27 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy |
| 14 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Fate Therapeutics, Inc. (“Fate” or the “Company”) is pleased to offer you an exempt full-time position as Chief Financial Officer, reporting to the Company’s President & Chief Executive Officer. This position has an anticipated start dat... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus e... |
| 30 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
The name of the plan is the Fate Therapeutics, Inc. Second Amended and Restated 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Con... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June |
| 05 Mar 2025 |
8-K: Results of Operations and Financial Condition
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE |
| 06 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective January 1, 2025 (the “Start Date”), J. Scott Wolchko (“Advisor”) and Fate Therapeutics, Inc. (“Company”) agree as follows pursuant to the instant agreement (“Advisory Agreement” or “Agreement”): |
| 29 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819 to Maintenance Therapy without Conditioning Chemotherapy Opened for Enrollment |
| 30 Aug 2024 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
This [Amended and Restated] Indemnification Agreement (“Agreement”) is made as of [________, 20__], by and between Fate Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). |
| 13 Aug 2024 |
8-K: Results of Operations and Financial Condition
Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as Alternative Conditioning Regimen |
Loading...